文献速递血栓与止血

延长抗凝与标准疗程预防首次非诱发性VTE复发及血栓后综合征的随机对照试验(ExACT研究)

A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study).
PubMed 文献 · Br J Haematol · 2019-11-12

Venous thromboembolism (VTE) is prevalent and impactful, with a risk of death, morbidity and recurrence. Post-thrombotic syndrome (PTS) is a common consequence and associated with impaired quality of life (QoL).…

要点

  • 延长抗凝显著降低首发非诱发性VTE复发风险,但大出血非显著增加。
  • 延长抗凝未降低血栓后综合征严重度或改善生活质量。
  • 抗凝治疗期间D-二聚体检测对预测VTE复发临床价值有限。

核心结论

  • 延长抗凝降低VTE复发但未减少PTS或改善生活质量,且大出血非显著增加。
  • 抗凝患者D-二聚体检测预测VTE复发的临床效用非常有限。

研究设计与样本

  • 非盲、前瞻性、多中心随机对照试验,比较延长与限定疗程抗凝。

主要发现

  • PTS严重度与生活质量两组无差异,抗凝中D-二聚体不预测VTE复发。

临床怎么用

  • 对首发非诱发性VTE完成≥3个月抗凝者,延长抗凝可显著降低复发但需权衡出血。
  • 不应依赖抗凝治疗中D-二聚体结果决定是否延长抗凝。
  • 延长抗凝不宜以降低PTS或改善生活质量为主要目的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is prevalent and impactful, with a risk of death, morbidity and recurrence. Post-thrombotic syndrome (PTS) is a common consequence and associated with impaired quality of life (QoL). The ExACT study was a non-blinded, prospective, multicentred randomised controlled trial comparing extended versus limited duration anticoagulation following a first unprovoked VTE (proximal deep vein thrombosis or pulmonary embolism). Adults were eligible if they had completed ≥3 months anticoagulation (remaining anticoagulated). The primary outcome was time to first recurrent VTE from randomisation. The secondary outcomes included PTS severity, bleeding, QoL and D-dimers. Two-hundred and eighty-one patients were recruited, randomised and followed up for 24 months (mean age 63, male:female 2:1). There was a significant reduction in recurrent VTE for patients receiving extended anticoagulation [2·75 vs. 13·54 events/100 patient years, adjusted hazard ratio (aHR) 0·20 (95% confidence interval (CI): 0·09 to 0·46, P < 0·001)] with a non-significant increase in major bleeding [3·54 vs. 1·18 events/100 patient years, aHR 2·99 (95% CI: 0·81-11·05, P = 0·10)]. Outcomes of PTS and QoL were no different between groups. D-dimer results (on anticoagulation) did not predict VTE recurrence. In conclusion, extended anticoagulation reduced VTE recurrence but did not reduce PTS or improve QoL and was associated with a non-significant increase in bleeding. Results also suggest very limited clinical utility of D-dimer testing on anticoagulated patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bradbury C, Fletcher K, Sun Y, et al. A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study). Br J Haematol. 2019. PMID: 31713863. doi:10.1111/bjh.16275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。